Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Study shows high SARS-CoV-2 seroprevalence, but low death rate in Malawi's health care workers

A study by researchers from Malawi and United Kingdom reveals a significant discrepancy between predicted coronavirus disease (COVID-19) mortality in the observed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence rates in health care workers and reported deaths in urban Malawi in southeastern Africa, indicating early exposure, but a slow progression of the outbreak. Their findings are currently available on the medRxiv preprint server.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

Oxford University and ZOE join forces to widen access to COVID-19 treatment trials

Oxford University and the COVID Symptom Study app are joining forces to widen access to two clinical trials of potential treatments for COVID-19.

3 Aug 2020

Cloth face masks have potential to reduce the transmission of SARS-CoV-2 viruses

A literature review coordinated by Karolinska Institutet in Sweden and McMaster University in Canada demonstrates that cloth face masks provide clinically useful levels of filtration, which has the potential to reduce the spread of viruses such as SARS-CoV-2.

3 Aug 2020

Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test

Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.

From Oxford Nanopore Technologies 3 Aug 2020

Photonics-based device could help COVID-19 patients with adequate treatments

Few could have foreseen the considerable impact that SARS-CoV-2 has had so far and is still having worldwide. Numbers continue to escalate and the complexity of the COVID-19 symptoms have hindered all efforts to optimize its treatment.

3 Aug 2020

Researchers identify transferrin as potential contributor to COVID-19 severity

SARS-CoV-2 is the coronavirus that causes COVID-19. It is currently not known why some individuals develop only mild or no symptoms when infected, whilst others experience severe, life-threatening forms of the disease.

3 Aug 2020

Immune system's oldest branches may underpin COVID severity

One of the immune system's oldest branches, called complement, may be influencing the severity of COVID disease, according to a new study from researchers at Columbia University Irving Medical Center.

3 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

Dexamethasone should be a standard drug in severe COVID-19

Many scientists have explored the use of new as well as already approved drugs for this condition, and one of the very few promising leads is dexamethasone. Dexamethasone is a corticosteroid, which has been reported in some earlier studies to reduce mortality in these patients by 18% and 36% in COVID-19 patients who are on oxygen and ventilators, respectively.

3 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

Severe fatigue common in COVID-19, independent of disease severity

Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.

2 Aug 2020

The race to a coronavirus vaccine

As the number of coronavirus disease (COVID-19) cases skyrocket to a staggering 18 million, the race to attain vaccine approval is on. More than a hundred candidate vaccines are being developed and tested to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, many vaccine candidates are undergoing human stage 2 and 3 trials to prove their efficacy and safety.

2 Aug 2020

There could be 7 million unplanned pregnancies because of COVID-19

The coronavirus pandemic has rippled across the globe, infecting nearly 18 million individuals worldwide to date. Though the coronavirus disease (COVID-19) affects people from all walks of life, women and girls may experience devastating effects of the outbreak.

2 Aug 2020

School children unlikely to play a significant role in COVID-19 spread, says Finnish study

A study conducted by researchers in Finland suggests that children who are exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in schools are unlikely to transmit the virus further and play any significant role in the spread of coronavirus disease 2019 (COVID-19).

2 Aug 2020

Pre-COVID-19 coronavirus antibodies fail to neutralize SARS-CoV-2

Researchers in Austria have shown that antibodies with potent neutralizing activity against a well-established seasonal coronavirus had no neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

By exploiting the tools of synthetic biology, the researchers from Turkey have successfully developed a de novo riboregulator system for rapidly detecting the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic material. Their paper is currently available on medRxiv preprint server.

2 Aug 2020

Study reveals attack rate of COVID-19 on trains

A study by scientists from the University of Southampton has examined the chances of catching COVID-19 in a train carriage carrying an infectious person.

1 Aug 2020